We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Palatin Technologies (PTN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Palatin Technologies is one of 978 individual stocks in the Medical sector. Collectively, these companies sit at #16 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PTN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PTN's full-year earnings has moved 30.77% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that PTN has returned about 39.01% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.52%. This shows that Palatin Technologies is outperforming its peers so far this year.
Breaking things down more, PTN is a member of the Medical - Biomedical and Genetics industry, which includes 444 individual companies and currently sits at #218 in the Zacks Industry Rank. This group has gained an average of 8.63% so far this year, so PTN is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to PTN as it looks to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Palatin Technologies (PTN - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Palatin Technologies is one of 978 individual stocks in the Medical sector. Collectively, these companies sit at #16 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. PTN is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PTN's full-year earnings has moved 30.77% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that PTN has returned about 39.01% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.52%. This shows that Palatin Technologies is outperforming its peers so far this year.
Breaking things down more, PTN is a member of the Medical - Biomedical and Genetics industry, which includes 444 individual companies and currently sits at #218 in the Zacks Industry Rank. This group has gained an average of 8.63% so far this year, so PTN is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to PTN as it looks to continue its solid performance.